市場調查報告書
商品編碼
1392199
心臟生物標記市場規模 - 按產品(肌鈣蛋白、CK-MB、肌紅蛋白、利鈉肽、CRP、缺血修飾白蛋白)、應用、最終用途 - 全球預測,2023-2032 年Cardiac Biomarkers Market Size - By Product (Troponins, CK-MB, Myoglobin, Natriuretic Peptides, CRP, Ischemia Modified Albumin), Application, End-use - Global Forecast, 2023-2032 |
2023年至2032年,心臟生物標記市場規模預計將達到12.8%的CAGR。全球心血管疾病盛行率不斷上升,加上人口老化,刺激了對先進診斷工具的需求。根據世界心臟聯盟(WHF)的最新報告,2021年有近2,050萬人死於心血管疾病(CVD)。
尖端技術的出現和對早期檢測的日益重視提高了心臟生物標記在臨床實踐中的重要性。這些生物標記,從蛋白質到遺傳標記物,正在成為醫療保健專業人員預測、診斷和管理心血管疾病不可或缺的工具,從而重塑心臟護理的模式。
心臟生物標記市場根據產品、應用、最終用途和地區進行分類。
預計到2032 年,利鈉肽領域將產生大量收入。利鈉肽,特別是B 型利鈉肽(BNP) 和N 末端B 型利鈉肽原(NT-proBNP),已成為心臟衰竭的關鍵指標。這些胜肽在檢測心臟壓力和功能障礙方面的精確度和敏感性引起了醫療保健提供者的廣泛關注。隨著技術的進步,新型利尿鈉肽檢測方法的開發有望提高診斷準確性,為臨床醫生提供強大的早期介入和個人化治療策略。
受全球心臟衰竭流行的推動,到 2032 年,充血性心臟衰竭 (CHF) 應用領域將對心臟生物標記產生大量需求。隨著 CHF 病例數量的驚人增加,CHF 生物標記譜,包括肌鈣蛋白、肌酸激酶-MB (CK-MB) 和肌紅蛋白,有助於心臟功能的全面評估。將這些生物標記整合到常規臨床實踐中正在重塑心臟衰竭的治療方法,以實現及時干預並改善患者預後。
歐洲心臟生物標記產業預計在 2023 年至 2032 年期間將錄得強勁的CAGR,這得益於心血管護理範式轉變,並且越來越重視預防措施和個人化醫療。在醫療機構和創新診斷公司之間的合作推動下,產品融入常規臨床實踐的勢頭正在增強。隨著歐洲地區繼續擁抱最新進展,市場預計將持續成長,開創整個歐洲大陸心血管保健的新時代。
Cardiac biomarkers market size is expected to record 12.8% CAGR from 2023 to 2032. The rising prevalence of cardiovascular diseases worldwide, coupled with an aging population, has spurred the need for advanced diagnostic tools. According to a new report from the World Heart Federation (WHF), nearly 20.5 million deaths happened due to cardiovascular (CVD) in 2021.
The advent of cutting-edge technologies and the growing emphasis on early detection have elevated the importance of cardiac biomarkers in clinical practice. These biomarkers, ranging from proteins to genetic markers, are becoming indispensable tools for healthcare professionals in predicting, diagnosing, and managing cardiovascular conditions, thus reshaping the landscape of cardiac care.
The cardiac biomarkers market is classified based on product, application, end-use, and region.
The natriuretic peptides segment is predicted to generate massive revenues by 2032. Natriuretic peptides, particularly B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), have become pivotal indicators for heart failure. The precision and sensitivity of these peptides in detecting cardiac stress and dysfunction have garnered widespread attention from healthcare providers. As technology advances, the development of novel natriuretic peptide assays promises enhanced diagnostic accuracy, providing clinicians with a powerful arsenal for early intervention and personalized treatment strategies.
The Congestive Heart Failure (CHF) application segment will generate high demand for cardiac biomarkers through 2032, driven by the global epidemic of heart failure. With a staggering rise in the number of CHF cases, the spectrum of CHF biomarkers, including troponins, creatine kinase-MB (CK-MB), and myoglobin, aid in the comprehensive evaluation of cardiac function. The integration of these biomarkers into routine clinical practice is reshaping the approach of managing heart failure, enabling timely interventions and improving patient outcomes.
Europe cardiac biomarkers industry is anticipated to record strong CAGR from 2023 to 2032, favored by a paradigm shift in cardiovascular care, with an increasing emphasis on preventive measures and personalized medicine. The product integration into routine clinical practice is gaining momentum, driven by collaborative efforts between healthcare institutions and innovative diagnostic companies. As the Europe region continues to embrace the latest advancements, the market is poised for sustained growth, ushering in a new era of cardiovascular healthcare across the continent.